Evidence map›Paper›PMID 31686214›Full record

ArticleHuman genetics2019

Association of rare non-coding SNVs in the lung-specific FOXF1 enhancer with a mitigation of the lethal ACDMPV phenotype.

Przemyslaw Szafranski, Qian Liu, Justyna A Karolak, Xiaofei Song, Nicole de Leeuw, Brigitte Faas, Romana Gerychova, Petr Janku, Marta Jezova, Iveta Valaskova and 8 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in Human genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Molecular Function and Contribution ofAmerican journal of respiratory and critical care medicine · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Long Non-Coding RNAGenes · 2021
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 5 countries.

Przemyslaw SzafranskiDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Qian LiuDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Justyna A KarolakDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Xiaofei SongDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Nicole de LeeuwDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Brigitte FaasDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Romana GerychovaDepartment of Obstetrics and Gynecology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
Petr JankuDepartment of Obstetrics and Gynecology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
Marta JezovaDepartment of Pathology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
Iveta ValaskovaDepartment of Medical Genetics, Masaryk University and University Hospital Brno, Brno, Czech Republic.
Kathleen A GibbsChildren's Hospital of Philadelphia, Philadelphia, PA, USA.
Lea F SurreyChildren's Hospital of Philadelphia, Philadelphia, PA, USA.
Virginie PoissonCHU Sainte-Justine, Montreal, Québec, Canada.
Denis BérubéCHU Sainte-Justine, Montreal, Québec, Canada.
Luc L OlignyCHU Sainte-Justine, Montreal, Québec, Canada.
Jacques L MichaudCHU Sainte-Justine, Montreal, Québec, Canada.
Edwina PopekDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Paweł StankiewiczDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA. pawels@bcm.edu.ORCID http://orcid.org/0000-0002-6456-7490
Baylor College of Medicine · USCentre Hospitalier Universitaire Sainte-Justine · CAMasaryk University · CZChildren's Hospital of Philadelphia · USRadboud University Nijmegen · NLPoznan University of Medical Sciences · PL

Funding

Epigenomic dysfunction at 16q24.1 vascular defects and perinatal consequencesR01HL137203 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI STANKIEWICZ, PAWEL · 2017 to 2020
$2.0M
National Organization for Rare Disorders 16001NHLBI NIH HHS R01 HL137203NHLBI NIH HHS R01HL137203
6 · The paper itself

Abstract

Haploinsufficiency of FOXF1 causes alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV), a lethal neonatal lung developmental disorder. We describe two similar heterozygous CNV deletions involving the FOXF1 enhancer and re-analyze FOXF1 missense mutation, all associated with an unexpectedly mitigated disease phenotype. In one case, the deletion of the maternal allele of the FOXF1 enhancer caused pulmonary hypertension and histopathologically diagnosed MPV without the typical ACD features. In the second case, the deletion of the paternal enhancer resulted in ACDMPV rather than the expected neonatal lethality. In both cases, FOXF1 expression in lung tissue was higher than usually seen or expected in patients with similar deletions, suggesting an increased activity of the remaining allele of the enhancer. Sequencing of these alleles revealed two rare SNVs, rs150502618-A and rs79301423-T, mapping to the partially overlapping binding sites for TFAP2s and CTCF in the core region of the enhancer. Moreover, in a family with three histopathologically-diagnosed ACDMPV siblings whose missense FOXF1 mutation was inherited from the healthy non-mosaic carrier mother, we have identified a rare SNV rs28571077-A within 2-kb of the above-mentioned non-coding SNVs in the FOXF1 enhancer in the mother, that was absent in the affected newborns and 13 unrelated ACDMPV patients with CNV deletions of this genomic region. Based on the low population frequencies of these three variants, their absence in ACDMPV patients, the results of reporter assay, RNAi and EMSA experiments, and in silico predictions, we propose that the described SNVs might have acted on FOXF1 enhancer as hypermorphs.

Indexed as

Enhancer Elements, GeneticMutation, MissensePolymorphism, Single NucleotideSequence DeletionAdultChildFemaleForkhead Transcription FactorsGenomic ImprintingHumansInfant, NewbornPersistent Fetal Circulation SyndromePhenotypePrognosisForkhead Transcription FactorsFOXF1 protein, human

Identifiers

PMID31686214
PMCPMC6874894
OpenAlexW2986546336

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.